Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Maggiolo

Showing results (61-70 of 150) with videos related to

Pageof 15
Sort By:
Patient Preference and Adherence|June 3, 2010
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsMonica Airoldi, Mauro Zaccarelli, Luca Bisi, et al.
Antiviral Therapy|November 3, 2010
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation scoreJonathan M Schapiro, Joseph Scherer, Charles A Boucher, et al.
Medicine|September 8, 2016
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation CohortNicola Squillace, Laura Galli, Alessandra Bandera, et al.
The Lancet. Infectious Diseases|October 25, 2011
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialJan van Lunzen, Franco Maggiolo, José R Arribas, et al.
The New Microbiologica|February 26, 2013
When phylogenetic analysis complements the epidemiological investigation: a case of HIV-2 infection, ItalyMassimo Ciccozzi, Annapaola Callegaro, Alessandra Lo Presti, et al.
AIDS (London, England)|May 8, 2025
Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infectionSabrina Marozin, Valeria Bono, Martina Mazzoccoli, et al.
AIDS (London, England)|September 10, 2002
Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patientsMario Clerici, Elena Seminari, Franco Maggiolo, et al.
AIDS Reviews|June 26, 2018
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical PracticeAntonio Di Biagio, Niccolò Riccardi, Stefano Rusconi, et al.
Journal of Global Antimicrobial Resistance|October 13, 2025
96-week real-world effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in HIV-infected adults with pre-existing NRTI resistance: A retrospective cohort studyLaura Mezzogori, Marco Muccio, Riccardo Schiavoni, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Pageof 15

Showing results (61-70 of 150) with videos related to

Sort By:
Pageof 15
Patient Preference and Adherence|June 3, 2010
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsMonica Airoldi, Mauro Zaccarelli, Luca Bisi, et al.
Antiviral Therapy|November 3, 2010
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation scoreJonathan M Schapiro, Joseph Scherer, Charles A Boucher, et al.
Medicine|September 8, 2016
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects: Data from the ICONA Foundation CohortNicola Squillace, Laura Galli, Alessandra Bandera, et al.
The Lancet. Infectious Diseases|October 25, 2011
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialJan van Lunzen, Franco Maggiolo, José R Arribas, et al.
The New Microbiologica|February 26, 2013
When phylogenetic analysis complements the epidemiological investigation: a case of HIV-2 infection, ItalyMassimo Ciccozzi, Annapaola Callegaro, Alessandra Lo Presti, et al.
AIDS (London, England)|May 8, 2025
Comparable gut mucosal breakdown and microbial translocation in severe COVID-19 with and without HIV infectionSabrina Marozin, Valeria Bono, Martina Mazzoccoli, et al.
AIDS (London, England)|September 10, 2002
Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patientsMario Clerici, Elena Seminari, Franco Maggiolo, et al.
AIDS Reviews|June 26, 2018
A Comprehensive Development Agenda on Tenofovir Alafenamide in Clinical PracticeAntonio Di Biagio, Niccolò Riccardi, Stefano Rusconi, et al.
Journal of Global Antimicrobial Resistance|October 13, 2025
96-week real-world effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in HIV-infected adults with pre-existing NRTI resistance: A retrospective cohort studyLaura Mezzogori, Marco Muccio, Riccardo Schiavoni, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Pageof 15